Insiders Aren’t Buying Pfizer Stock, and That Could Help
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
This piece outlines What To Buy After Tax Loss Harvest Dividend ETF, including replacement candidates and criteria to choose wisely.
23,181 articlesPfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Cash flow from senior housing and warehouse REITs is holding steady even as refinancing costs rise. The payout outloo...
With market volatility on the rise, investors are turning to high-yield dividend plays. Three U.S. names stand out fo...
Strategy’s perpetual preferred stock has fallen from the $100 issuance price to the mid-$70s, prompting widespread in...
Strategy reports a second BTC sale in six weeks, expanding liquidity and reshaping long-term exposure to crypto.
Three blue-chip names have slipped on the chart while trading below intrinsic value, offering income and upside for p...
As 2026 unfolds, Caesars Entertainment and Six Flags chart different courses in the leisure market. This guide breaks...
As AI drives demand for faster memory, Micron sits at the center of a cyclical industry that can fuel outsized moves....
As April 2026 approaches, investors face AI chatter, geopolitical headlines, and macro uncertainty. This guide offers...
New to crypto? This expert guide lays out beginner's picks for crypto investments, plus practical steps to buy safely...
A new PWBM study places the insolvency deadline for Social Security's trust fund at 2032, six years from now. It eval...
Lawmakers remain at an impasse on reforms as Social Security heads toward solvency risk in roughly six years. The inv...